Private equity firm JLL Partners makes moves on CROs
This article was originally published in Scrip
The US private equity company JLL Partners has signed a definitive agreement to acquire the CRO PharmaNet, just a couple of months after saying that it intended to make an unsolicited bid for restricted voting shares of the CRO and manufacturer, Patheon.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.